Fundraising announcement:
Orakl Oncology Raises €11 million to Launch First-in-class AI-powered Drug Development Products for Biopharma and Biotech
Fundraising announcement:
Orakl Oncology Raises €11 million to Launch First-in-class AI-powered Drug Development Products for Biopharma and Biotech
Pioneering precision oncology company Orakl raised €11 million in seed funding, led by Singular with participation from existing investors.
The funding will fuel the development of Orakl’s business unit and will prepare the company for strategic collaborations with pharmaceutical partners.
Orakl is now marketing its two first AI-powered commercial solutions to reinvent oncology drug development.
Paris, 3rd December 2024 - Orakl Oncology (“Orakl”), a pioneering precision oncology company, announced today an €11 million seed funding round, led by Singular, with support from Bpifrance including the Grand Prix i-Lab, and participation from existing investors. This new funding will be used to accelerate the company's growth and support the launch of two new commercial products, O-Predict and O-Validate designed to transform the landscape of oncology drug development.
Founded in 2023 by Fanny Jaulin, PhD, Diane-Laure Pagès, PhD, and Gustave Ronteix, PhD, Orakl is a spin-off from the Gustave Roussy Institute - the leading European cancer research institute. The company is addressing a critical challenge in oncology, where only 4% of drug candidates will reach cancer patients. The majority of drugs fail in clinical trials due to inaccurate and disjointed decisions made from heterogeneous data and models that do not translate well in humans. To solve this challenge, Orakl has developed a first-in-class, AI-powered techbio platform that combines real-world patient data with cutting-edge biology into a unique and integrated decision-making engine for the entire drug development process. Orakl’s technology delivers best-in-class predictions to significantly improve the recruitment of responding patients and clinical trial probability of success. This fulfills Orakl’s mission: transforming the oncology drug development landscape and providing more drugs to patients, faster.
Dr. Fanny Jaulin, Orakl Oncology CEO & Co-Founder, commented: “Our mission at Orakl is to revolutionize drug development by offering an unparalleled decision-making platform that empowers drug developers to de-risk clinical trials and expedite the availability of new transformative medicines. By addressing the urgent unmet needs in digestive cancers, we aim to redefine the future of precision medicine and deliver breakthroughs that patients desperately need."
Leveraging machine learning, advanced cell biology and engineering, Orakl’s platform is powered by hundreds of individualized patient avatars that combine rich, longitudinal real-world data and sustainable tissues from the same patient to simulate real-life drug responses. Initially focusing on colorectal and pancreatic cancers - two major unmet medical needs - the company’s growing collection of patient avatars helps pharmaceutical and biotech companies predict and optimize clinical trial outcomes, discover and validate new therapeutic targets, and identify optimal drug combinations or competitive threats*. Orakl also plans to use the platform to inform in-licensing decisions and build its own internal pipeline.
Prof. Fabrice Barlesi, General Director of Gustave Roussy, commented: "As Europe’s leading cancer center and a pioneer in precision medicine, we are proud to innovate through our spin-off, Orakl, which develops ex vivo patient avatars for therapeutic decision-making and accelerates the discovery of next-generation cancer therapies."
Building on this foundation, Orakl is now marketing its two first AI-powered commercial solutions to reinvent oncology drug development. The first solution, O-Predict, forecasts patient responses to new drug candidates, predicting key clinical outcomes such as the number of responders and progression-free survival. It also evaluates the efficacy of these new treatments against standard or competitor therapies, designs combinatorial treatments, and identifies multimodal predictive biomarkers. Orakl’s second product, O-Validate, provides biological evidence of causality, supporting target and biomarker validation and enabling data-based strategic decision-making across drug development stages.
Jeremy Uzan, General Partner at Singular, commented: "A key strength of Orakl lies in its team - a mix of deep expertise in cancer research, cell biology, and computational biology. With the recent addition of Jessica Atkinson as Business Advisor, the company is better positioned than ever to forge strategic partnerships in the pharmaceutical sector. Backed by a solid scientific foundation and a clear business focus, Orakl is set to drive meaningful progress in oncology—and we are proud to support the team on this journey."
The new investment will enable Orakl to build its business unit and position the company for strategic partnerships within the pharmaceutical sector. To lead this initiative, Orakl has appointed Jessica Atkinson as Business Advisor. As a business expert with extensive experience at Merck and Foundation Medicine, she will develop and execute a strategic approach to drive Orakl’s entry into the clinical oncology market. In addition, Orakl is building a dedicated business team to support its new commercial offerings expecting to transform drug development in the era of precision oncology.
This investment follows a €3M pre-seed round in October 2023 led by Speedinvest with participation from HCVC and Verve Ventures. Together with the award from the Fondation Jean-Jacques et Felicia Lopez Loreta pour l’Excellence Scientifique, this brings Orakl's total capital raised to date to nearly €15 million.
*Communicated at ESMO conference - Barcelona september 2024
For more information, please contact:
Orakl Oncology
Fanny Jaulin, CEO and Co-Founder
E: contact@orakl-oncology.com
W: https://www.orakl-oncology.com/
Pioneering precision oncology company Orakl raised €11 million in seed funding, led by Singular with participation from existing investors.
The funding will fuel the development of Orakl’s business unit and will prepare the company for strategic collaborations with pharmaceutical partners.
Orakl is now marketing its two first AI-powered commercial solutions to reinvent oncology drug development.